Intensive scientific investigation remains the bedrock of progress in the Klippel-Trenaunay Syndrome (KTS) treatment arena, driving clinical innovation and market evolution. The field of Klippel-Trenaunay Syndrome Treatment research has recently experienced a breakthrough with the identification of somatic mutations in the PIK3CA gene as a primary etiological factor. This discovery has...